A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Evinacumab in Healthy Japanese and Caucasian Subjects
Phase of Trial: Phase I
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Evinacumab (Primary) ; Evinacumab (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 30 Nov 2017 Study protocol has been amended for this trial and multiple fields in the profile are changed. Purpose and title is changed. Study design changed from parallel to sequential. No.of treatment arms changed from 3 to 4 and therefore no. of patients changed from 72 to 96. Time frame for primary end point is changed from week 28 to 31.
- 30 Nov 2017 Planned number of patients changed from 72 to 96.
- 30 Nov 2017 Planned End Date changed from 1 Dec 2017 to 13 Jun 2018.